Navigation Links
Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
Date:9/6/2013

SAN DIEGO, Sept. 6, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Bank of America Merrill Lynch Global Healthcare Conference in London. The presentation is scheduled for Thursday, September 12th at 9:30 a.m. London Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com

 

Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
2. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
3. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
4. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
5. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
6. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
7. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
8. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
9. Orexigen Therapeutics to Present at Upcoming Investor Conferences
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... July 14, 2014  Mylan Inc. (NASDAQ: MYL ... agreement with Abbott (NYSE: ... non-U.S. developed markets specialty and branded generics business ("the ... will receive 105 million shares of the combined ... of $50.20 on Friday, July 11, 2014, representing an approximately ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... report to their offering. ... hollow needle commonly used with a syringe to inject ... from it. A hypodermic needle is used for rapid ... be ingested. Hypodermic needles are broadly classified into non-safety ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... 11, 2010 Thoratec Corporation (Nasdaq: THOR ... therapies to save, support and restore failing hearts, said ... Tuesday, November 16 at the American Heart Association (AHA) ... and chief executive officer of Thoratec, will be discussing ...
... 2010 Ardea Biosciences, Inc. (Nasdaq: RDEA ... trials of BAY 86-9766 (formerly known as RDEA119) will ... and Treatment of Cancer (EORTC) – National Cancer Institute ... on "Molecular Targets and Cancer Therapeutics" in Berlin, Germany. ...
Cached Medicine Technology:Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 3Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 4
(Date:7/14/2014)... The report “Biofertilizers Market ... Type (Cereals & Grains, Pulses & Oilseeds, ... Azospirillium, Cyanobacteria, Phosphate solubilizing bacteria), & by ... 2019” defines and segments the biofertilizers market ... values for the market. It also identifies ...
(Date:7/14/2014)... E.J. Mundell ... News) -- When an 11-year-old boy in San Diego ... the nickel in his family,s iPad. They also ... iPad,s metal surfaces with a form-fitting case. The ... personal effects as potential sources of nickel exposure" and ...
(Date:7/14/2014)... specialists look back on 40 years of the Glasgow Coma ... research and clinical practice, in a new Personal View published ... The Personal View is published on the 40th anniversary of ... Since this seminal publication, the Glasgow Coma Scale has ... conscious level, the clinical hallmark of acute brain injury. The ...
(Date:7/14/2014)... to ignore irrelevant stimuli underlies the impaired working memory ... reports a new study in the current issue of ... good at focusing on the information that we are ... thoughts that aren,t relevant. However, memory impairment in schizophrenia ... this filtering process, which Dr. Teal Eich at Columbia ...
(Date:7/14/2014)... N.J. (PRWEB) July 14, 2014 Documented ... Laurel, has announced the publication of its first military memoir ... crash on Black Thursday in October 1943 and 19 months ... to return home and build the American dream. , ... and the American dream (Amazon) is a true ...
Breaking Medicine News(10 mins):Health News:Biofertilizers Market worth $1,649.7 Million by 2019 - A Report by MarketsandMarkets 2Health News:Biofertilizers Market worth $1,649.7 Million by 2019 - A Report by MarketsandMarkets 3Health News:Biofertilizers Market worth $1,649.7 Million by 2019 - A Report by MarketsandMarkets 4Health News:iPads Can Trigger Nickel Allergies in Kids 2Health News:'Noisy' memory in schizophrenia 2Health News:Mount Laurel-based Documented Legacy to Release Military Memoir of World War II Air Force Vet Who Survived Black Thursday Crash 2
... HealthDay Reporter , FRIDAY, March 16 (HealthDay ... for kids who have a genetic predisposition to aggressive ... new research suggests. "There,s an intricate interplay between ... assistant professor of criminology at the University of Texas ...
... Musicians and their instruments often make beautiful music together, but ... of musical instruments may put their owners at risk for ... Contact dermatitis is a rash caused by an irritant or ... components of musical instruments -- such as metals, exotic woods ...
... Obesity appears to significantly increase the risk of death ... mortality even among those prescribed 18 or fewer pills ... as a marker of increased vulnerability," said Robert Langer, ... and Prevention | Nutrition, Physical Activity and Metabolism 2012 ...
... companies in overcoming common issues associated with crystal formation ... The software, which has been developed at the University ... Centre (CCDC) is called Visual HABIT. It offers a ... companies to adopt a more ,bottom up, approach to ...
... , FRIDAY, March 16 (HealthDay News) -- People with ... risk for health problems that affect the heart, an ... of psoriasis. Chronic inflammation is also a characteristic of ... said Dr. Joel Gelfand, an assistant professor of dermatology ...
... facilitate efficient production of chemicals, materials and fuels from ... Excellence (CoE) in White Biotechnology Green Chemistry Research ... or cell factories, for producing new useful compounds from ... for example, for manufacturing bioplastics or in medical applications. ...
Cached Medicine News:Health News:With Spanking, Nature and Nurture Create More Aggression, Study Suggests 2Health News:With Spanking, Nature and Nurture Create More Aggression, Study Suggests 3Health News:Tooting Your Horn Can Raise Risk for Skin Condition 2Health News:Obesity raises death risk tied to sleeping pills 2Health News:Obesity raises death risk tied to sleeping pills 3Health News:New technology to aid crystallization prediction 2Health News:Psoriasis Patients May Face Higher Heart Risk 2Health News:Novel plastics and textiles from waste with the use of microbes 2